Related references
Note: Only part of the references are listed.Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
Maurizio Callari et al.
CLINICAL CANCER RESEARCH (2016)
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2016)
Clinical implications of the intrinsic molecular subtypes of breast cancer
Aleix Prat et al.
BREAST (2015)
Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy
Adam D. Pfefferle et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Maggie C. U. Cheang et al.
ONCOLOGIST (2015)
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
M. Gnant et al.
ANNALS OF ONCOLOGY (2014)
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
A. Prat et al.
BRITISH JOURNAL OF CANCER (2014)
Intrinsic Subtypes from the PAM50 Gene Expression Assay in a Population-Based Breast Cancer Survivor Cohort: Prognostication of Short- and Long-term Outcomes
Bette J. Caan et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer
Martin Filipits et al.
CLINICAL CANCER RESEARCH (2014)
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2014)
New Strategies for Triple-Negative Breast Cancer-Deciphering the Heterogeneity
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2014)
Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Miguel Martin et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
E. H. Lips et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice
Jerry Usary et al.
CLINICAL CANCER RESEARCH (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer
Christine E. Horak et al.
CLINICAL CANCER RESEARCH (2013)
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
Aleix Prat et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Aleix Prat et al.
ONCOLOGIST (2013)
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
A. Prat et al.
ANNALS OF ONCOLOGY (2012)
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
Roy R. L. Bastien et al.
BMC MEDICAL GENOMICS (2012)
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Laura J. Esserman et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer
A. Prat et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer
Tomohiro Miyake et al.
CANCER SCIENCE (2012)
A Mammary Stem Cell Population Identified and Characterized in Late Embryogenesis Reveals Similarities to Human Breast Cancer
Benjamin T. Spike et al.
CELL STEM CELL (2012)
Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
Maggie C. U. Cheang et al.
CLINICAL CANCER RESEARCH (2012)
A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
Stephen K. Chia et al.
CLINICAL CANCER RESEARCH (2012)
Practical implications of gene-expression-based assays for breast oncologists
Aleix Prat et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer
Xi Chen et al.
CANCER INFORMATICS (2012)
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures
Cheng Fan et al.
BMC MEDICAL GENOMICS (2011)
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Deconstructing the molecular portraits of breast cancer
Aleix Prat et al.
MOLECULAR ONCOLOGY (2011)
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
Torsten O. Nielsen et al.
CLINICAL CANCER RESEARCH (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Lao H. Saal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Gene expression patterns associated with p53 status in breast cancer
Melissa A. Troester et al.
BMC CANCER (2006)
DAVID: Database for annotation, visualization, and integrated discovery
G Dennis et al.
GENOME BIOLOGY (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
